新浪登录
腾讯登录Sci Transl Med：开发出抵御尼帕病毒感染的新型疫苗
| 导读 | 近日，来自研究者的最新研究报告，他们成功在猴子模型中检测了抵御尼帕病毒（Nipah virus）的新型疫苗。尼帕病毒是1998年在东南亚地区发现的在猪和养猪户之间互相传播的人类致病微生物。早期的研究工作揭示了新型疫苗可以保护猫类避免该病毒的感染。研究者的相关研究成果刊登在了近日的国际杂志<em>Science Translational Medicine</em>上。
... |
近日，来自研究者的最新研究报告，他们成功在猴子模型中检测了抵御尼帕病毒（Nipah virus）的新型疫苗。尼帕病毒是1998年在东南亚地区发现的在猪和养猪户之间互相传播的人类致病微生物。早期的研究工作揭示了新型疫苗可以保护猫类避免该病毒的感染。研究者的相关研究成果刊登在了近日的国际杂志<em>Science Translational Medicine</em>上。
所有病毒在人类中都有高的致死率，超过75%的尼帕病毒和60%的亨得拉病毒(Hendra virus)以人类的肺部和大脑为感染靶点，在过去的10年里，这种疾病常常有规律的爆发，两种病毒极其相近。尼帕病毒的爆发发生在马来西亚、印度、孟加拉国和新加坡，而亨得拉病毒主要在澳大利亚爆发。
<!--more-->
研究者基于亨得拉病毒的表面蛋白来进行研究，其表面蛋白G糖蛋白是熟知的引发保护性宿主免疫系统的主要靶点，研究者使用感染尼帕病毒的非洲旅游模型来进行实验，检测了3中不同剂量的疫苗和佐剂混合物在模型中的效应。结果显示，在初次注射后的42天里，所有的研究模型都存活了下来。
研究小组计划进行深入研究来收集更多的数据包括美国FDA关于疫苗的许可及相关规定等，总的来说研究者的新型疫苗对于治疗疾病带来了很大的希望。
编译自：<a title="" href="http://www.sciencedaily.com/releases/2012/08/120808142154.htm" target="_blank">Test Vaccine Successfully Protects Monkeys from Nipah Virus</a>
<div id="ztload">
<div> </div>
<div>
<div>
<img src="http://www.bioon.com/biology/UploadFiles/201208/2012080922191224.jpg" alt="" width="113" height="149" border="0" />
<a title="" href="http://dx.doi.org/doi:10.1126/scitranslmed.3004241" target="_blank">doi:10.1126/scitranslmed.3004241</a>
PMC:
PMID:
</div>
<div>
<br/><strong>A Hendra Virus G Glycoprotein Subunit Vaccine Protects African Green Monkeys from Nipah Virus Challenge</strong><br/>
Katharine N. Bossart1,2,*, Barry Rockx3,4,*, Friederike Feldmann5, Doug Brining6, Dana Scott6, Rachel LaCasse6, Joan B. Geisbert7,8, Yan-Ru Feng9, Yee-Peng Chan9, Andrew C. Hickey1,2, Christopher C. Broder9,†, Heinz Feldmann3,10 and Thomas W. Geisbert7,8
In the 1990s, Hendra virus and Nipah virus (NiV), two closely related and previously unrecognized paramyxoviruses that cause severe disease and death in humans and a variety of animals, were discovered in Australia and Malaysia, respectively. Outbreaks of disease have occurred nearly every year since NiV was first discovered, with case fatality ranging from 10 to 100%. In the African green monkey (AGM), NiV causes a severe lethal respiratory and/or neurological disease that essentially mirrors fatal human disease. Thus, the AGM represents a reliable disease model for vaccine and therapeutic efficacy testing. We show that vaccination of AGMs with a recombinant subunit vaccine based on the henipavirus attachment G glycoprotein affords complete protection against subsequent NiV infection with no evidence of clinical disease, virus replication, or pathology observed in any challenged subjects. Success of the recombinant subunit vaccine in nonhuman primates provides crucial data in supporting its further preclinical development for potential human use.
<br/>来源：生物谷
</div>
</div>
</div>
所有病毒在人类中都有高的致死率，超过75%的尼帕病毒和60%的亨得拉病毒(Hendra virus)以人类的肺部和大脑为感染靶点，在过去的10年里，这种疾病常常有规律的爆发，两种病毒极其相近。尼帕病毒的爆发发生在马来西亚、印度、孟加拉国和新加坡，而亨得拉病毒主要在澳大利亚爆发。
<!--more-->
研究者基于亨得拉病毒的表面蛋白来进行研究，其表面蛋白G糖蛋白是熟知的引发保护性宿主免疫系统的主要靶点，研究者使用感染尼帕病毒的非洲旅游模型来进行实验，检测了3中不同剂量的疫苗和佐剂混合物在模型中的效应。结果显示，在初次注射后的42天里，所有的研究模型都存活了下来。
研究小组计划进行深入研究来收集更多的数据包括美国FDA关于疫苗的许可及相关规定等，总的来说研究者的新型疫苗对于治疗疾病带来了很大的希望。
编译自：<a title="" href="http://www.sciencedaily.com/releases/2012/08/120808142154.htm" target="_blank">Test Vaccine Successfully Protects Monkeys from Nipah Virus</a>
<div id="ztload">
<div> </div>
<div>
<div>
<img src="http://www.bioon.com/biology/UploadFiles/201208/2012080922191224.jpg" alt="" width="113" height="149" border="0" />
<a title="" href="http://dx.doi.org/doi:10.1126/scitranslmed.3004241" target="_blank">doi:10.1126/scitranslmed.3004241</a>
PMC:
PMID:
</div>
<div>
<br/><strong>A Hendra Virus G Glycoprotein Subunit Vaccine Protects African Green Monkeys from Nipah Virus Challenge</strong><br/>
Katharine N. Bossart1,2,*, Barry Rockx3,4,*, Friederike Feldmann5, Doug Brining6, Dana Scott6, Rachel LaCasse6, Joan B. Geisbert7,8, Yan-Ru Feng9, Yee-Peng Chan9, Andrew C. Hickey1,2, Christopher C. Broder9,†, Heinz Feldmann3,10 and Thomas W. Geisbert7,8
In the 1990s, Hendra virus and Nipah virus (NiV), two closely related and previously unrecognized paramyxoviruses that cause severe disease and death in humans and a variety of animals, were discovered in Australia and Malaysia, respectively. Outbreaks of disease have occurred nearly every year since NiV was first discovered, with case fatality ranging from 10 to 100%. In the African green monkey (AGM), NiV causes a severe lethal respiratory and/or neurological disease that essentially mirrors fatal human disease. Thus, the AGM represents a reliable disease model for vaccine and therapeutic efficacy testing. We show that vaccination of AGMs with a recombinant subunit vaccine based on the henipavirus attachment G glycoprotein affords complete protection against subsequent NiV infection with no evidence of clinical disease, virus replication, or pathology observed in any challenged subjects. Success of the recombinant subunit vaccine in nonhuman primates provides crucial data in supporting its further preclinical development for potential human use.
<br/>来源：生物谷
</div>
</div>
</div>
还没有人评论，赶快抢个沙发